Physician profile
Michael J Joyce
NPI 1174614192
$1,398.45
in general payments reported to CMS, 2019-2025
16 companies · $52.50 in 2025
The $52.50 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $114 · 2021: $12.60 · 2022: $53.02 · 2023: $425 · 2024: $457 · 2025: $52.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.79 |
| Education | $130.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $317.98 | 2019-2024 | |
| Sobi, INC | $280.18 | 2019-2024 | |
| Pfizer INC. | $185.10 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $149.25 | 2019-2024 | Ultomiris, Koselugo |
| Novo Nordisk INC | $100.18 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $89.01 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.24 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $49.52 | 2019-2024 | |
| Seagen INC. | $32.71 | 2023 | Adcetris |
| Csl Behring | $31.17 | 2025 | Afstyla, Idelvion |
| Genentech USA, INC. | $25.70 | 2023 | Hemlibra |
| Day One Biopharmaceuticals | $24.45 | 2024 | Ojemda |
| Uswm, LLC | $20.46 | 2024 | Iwilfin |
| Daiichi Sankyo INC. | $17.19 | 2019 | |
| Glaxosmithkline, LLC. | $12.60 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.